{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T17:40:10Z","timestamp":1752514810515,"version":"3.41.2"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,14]]},"DOI":"10.7759\/cureus.87910","type":"journal-article","created":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T17:24:21Z","timestamp":1752513861000},"source":"Crossref","is-referenced-by-count":0,"title":["Choosing the Right Vasoactive Agent in Acute Variceal Bleeding in Cirrhotic Patients: A Review of Terlipressin vs. Octreotide Outcomes"],"prefix":"10.7759","author":[{"given":"Moses John","family":"Wesley","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anjali","family":"Avula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hafsa","family":"Tehniyat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Hamza","family":"Zamir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umer","family":"Farooq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fizza","family":"Tahir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Almas","family":"Akbar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirshan","family":"Lal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine S","family":"Trejos Guzman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad M","family":"Tariq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Samaat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdul Haseeb","family":"Hasan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.5009\/gnl19155","article-title":"Treatment outcomes and prognostic factors of acute variceal bleeding in patients with hepatocellular carcinoma","volume":"14","author":"Lee YR","year":"2020","unstructured":"Lee YR, Park SY, Tak WY. Treatment outcomes and prognostic factors of acute variceal bleeding in patients with hepatocellular carcinoma. Gut Liver. 2020, 14:500-8. 10.5009\/gnl19155","journal-title":"Gut Liver"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/750150","article-title":"Prevention and management of gastroesophageal varices in cirrhosis","volume":"2012","author":"Chen YI","year":"2012","unstructured":"Chen YI, Ghali P. Prevention and management of gastroesophageal varices in cirrhosis. Int J Hepatol. 2012, 2012:750150. 10.1155\/2012\/750150","journal-title":"Int J Hepatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1177\/17562848221101712","article-title":"Management of varices and variceal hemorrhage in liver cirrhosis: a recent update","volume":"15","author":"Diaz-Soto MP","year":"2022","unstructured":"Diaz-Soto MP, Garcia-Tsao G. Management of varices and variceal hemorrhage in liver cirrhosis: a recent update. Therap Adv Gastroenterol. 2022, 15:17562848221101712. 10.1177\/17562848221101712","journal-title":"Therap Adv Gastroenterol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000685","article-title":"The current applications and future directions of terlipressin","volume":"9","author":"Liu D","year":"2025","unstructured":"Liu D, Testro A, Majumdar A, Sinclair M. The current applications and future directions of terlipressin. Hepatol Commun. 2025, 9:e0685. 10.1097\/HC9.0000000000000685","journal-title":"Hepatol Commun"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1582-4934.2008.00218.x","article-title":"The somatostatin analogue octreotide inhibits angiogenesis in the earliest, but not in advanced, stages of portal hypertension in rats","volume":"12","author":"Mejias M","year":"2008","unstructured":"Mejias M, Garcia-Pras E, Tiani C, Bosch J, Fernandez M. The somatostatin analogue octreotide inhibits angiogenesis in the earliest, but not in advanced, stages of portal hypertension in rats. J Cell Mol Med. 2008, 12:1690-9. 10.1111\/j.1582-4934.2008.00218.x","journal-title":"J Cell Mol Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.4253\/wjge.v3.i5.95","article-title":"Comparison between endoscopic sclerotherapy and band ligation for hemostasis of acute variceal bleeding","volume":"3","author":"Luz GO","year":"2011","unstructured":"Luz GO, Maluf-Filho F, Matuguma SE, et al.. Comparison between endoscopic sclerotherapy and band ligation for hemostasis of acute variceal bleeding. World J Gastrointest Endosc. 2011, 3:95-100. 10.4253\/wjge.v3.i5.95","journal-title":"World J Gastrointest Endosc"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1177\/1524839919893361","article-title":"A review of the PubMed PICO tool: using evidence-based practice in health education","volume":"21","author":"Brown D","year":"2020","unstructured":"Brown D. A review of the PubMed PICO tool: using evidence-based practice in health education. Health Promot Pract. 2020, 21:496-8. 10.1177\/1524839919893361","journal-title":"Health Promot Pract"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2008.147","article-title":"Terlipressin vs. octreotide in bleeding esophageal varices as an adjuvant therapy with endoscopic band ligation: a randomized double-blind placebo-controlled trial","volume":"104","author":"Abid S","year":"2009","unstructured":"Abid S, Jafri W, Hamid S, et al.. Terlipressin vs. octreotide in bleeding esophageal varices as an adjuvant therapy with endoscopic band ligation: a randomized double-blind placebo-controlled trial. Am J Gastroenterol. 2009, 104:617-23. 10.1038\/ajg.2008.147","journal-title":"Am J Gastroenterol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.21037\/atm-20-6774","article-title":"The pharmacodynamic effect of terlipressin versus high-dose octreotide in reducing hepatic venous pressure gradient: a randomized controlled trial","volume":"9","author":"Li B","year":"2021","unstructured":"Li B, Chen J, Zhang CQ, et al.. The pharmacodynamic effect of terlipressin versus high-dose octreotide in reducing hepatic venous pressure gradient: a randomized controlled trial. Ann Transl Med. 2021, 9:793. 10.21037\/atm-20-6774","journal-title":"Ann Transl Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(19)30090-1","article-title":"Early TIPS with covered stents versus standard treatment for acute variceal bleeding in patients with advanced cirrhosis: a randomised controlled trial","volume":"4","author":"Lv Y","year":"2019","unstructured":"Lv Y, Yang Z, Liu L, et al.. Early TIPS with covered stents versus standard treatment for acute variceal bleeding in patients with advanced cirrhosis: a randomised controlled trial. Lancet Gastroenterol Hepatol. 2019, 4:587-98. 10.1016\/S2468-1253(19)30090-1","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27006","article-title":"Lack of difference among terlipressin, somatostatin, and octreotide in the control of acute gastroesophageal variceal hemorrhage","volume":"60","author":"Seo YS","year":"2014","unstructured":"Seo YS, Park SY, Kim MY, et al.. Lack of difference among terlipressin, somatostatin, and octreotide in the control of acute gastroesophageal variceal hemorrhage. Hepatology. 2014, 60:954-63. 10.1002\/hep.27006","journal-title":"Hepatology"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2005.41381.x","article-title":"Acute hemodynamic effects of octreotide and terlipressin in patients with cirrhosis: a randomized comparison","volume":"100","author":"Baik SK","year":"2005","unstructured":"Baik SK, Jeong PH, Ji SW, et al.. Acute hemodynamic effects of octreotide and terlipressin in patients with cirrhosis: a randomized comparison. Am J Gastroenterol. 2005, 100:631-5. 10.1111\/j.1572-0241.2005.41381.x","journal-title":"Am J Gastroenterol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1097\/MS9.0000000000001261","article-title":"Continuous vs. intermittent terlipressin infusion for portal hypertension: a systematic review and meta-analysis","volume":"85","author":"Hassan M","year":"2023","unstructured":"Hassan M, Merza N, Nawras Y, et al.. Continuous vs. intermittent terlipressin infusion for portal hypertension: a systematic review and meta-analysis. Ann Med Surg (Lond). 2023, 85:5001-10. 10.1097\/MS9.0000000000001261","journal-title":"Ann Med Surg (Lond)"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2001.22529","article-title":"Octreotide potentiates PKC-dependent vasoconstrictors in portal-hypertensive and control rats","volume":"120","author":"Wiest R","year":"2001","unstructured":"Wiest R, Tsai MH, Groszmann RJ. Octreotide potentiates PKC-dependent vasoconstrictors in portal-hypertensive and control rats. Gastroenterology. 2001, 120:975-83. 10.1053\/gast.2001.22529","journal-title":"Gastroenterology"},{"key":"ref17","article-title":"American Association for the Study of Liver Diseases (AASLD)-56th annual meeting","volume":"9","author":"Phend C","year":"2006","unstructured":"Phend C. American Association for the Study of Liver Diseases (AASLD)-56th annual meeting. IDrugs. 2006, 9:96-100.","journal-title":"IDrugs"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1177\/17562848221098253","article-title":"Practice guidance for the use of terlipressin for liver cirrhosis-related complications","volume":"15","author":"Qi X","year":"2022","unstructured":"Qi X, Bai Z, Zhu Q, et al.. Practice guidance for the use of terlipressin for liver cirrhosis-related complications. Therap Adv Gastroenterol. 2022, 15:17562848221098253. 10.1177\/17562848221098253","journal-title":"Therap Adv Gastroenterol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrc.2025.155038","article-title":"Multisystem hemodynamic effects of terlipressin in cirrhosis: a scoping review","volume":"87","author":"Skvarce J","year":"2025","unstructured":"Skvarce J, Bui A, Oro P, et al.. Multisystem hemodynamic effects of terlipressin in cirrhosis: a scoping review. J Crit Care. 2025, 87:155038. 10.1016\/j.jcrc.2025.155038","journal-title":"J Crit Care"},{"key":"ref20","article-title":"Octreotide","author":"Debnath D","year":"2023","unstructured":"Debnath D, Cheriyath P. Octreotide. StatPearls. StatPearls Publishing, Treasure Island, FL; 2023."},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-56873-x","article-title":"Real-world comparison of terlipressin vs. octreotide as an adjuvant treatment in the management of variceal bleeding","volume":"14","author":"Rehman H","year":"2024","unstructured":"Rehman H, Rehman ST, Zulfiqar S, Awan S, Abid S. Real-world comparison of terlipressin vs. octreotide as an adjuvant treatment in the management of variceal bleeding. Sci Rep. 2024, 14:6692. 10.1038\/s41598-024-56873-x","journal-title":"Sci Rep"},{"key":"ref22","article-title":"Role of pharmacogenomic biomarkers in predicting and improving drug response: part 1: the clinical significance of pharmacogenetic variants","volume":"38","author":"Ventola CL","year":"2013","unstructured":"Ventola CL. Role of pharmacogenomic biomarkers in predicting and improving drug response: part 1: the clinical significance of pharmacogenetic variants. P T. 2013, 38:545-60.","journal-title":"P T"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1124\/pharmrev.122.000810","article-title":"Pharmacogenomics: driving personalized medicine","volume":"75","author":"Sadee W","year":"2023","unstructured":"Sadee W, Wang D, Hartmann K, Toland AE. Pharmacogenomics: driving personalized medicine. Pharmacol Rev. 2023, 75:789-814. 10.1124\/pharmrev.122.000810","journal-title":"Pharmacol Rev"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/379398-choosing-the-right-vasoactive-agent-in-acute-variceal-bleeding-in-cirrhotic-patients-a-review-of-terlipressin-vs-octreotide-outcomes","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T17:24:22Z","timestamp":1752513862000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/379398-choosing-the-right-vasoactive-agent-in-acute-variceal-bleeding-in-cirrhotic-patients-a-review-of-terlipressin-vs-octreotide-outcomes"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,14]]},"references-count":23,"URL":"https:\/\/doi.org\/10.7759\/cureus.87910","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,14]]}}}